Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | IDE | P14735 | 1/20 | 0.65 |
| ▸ | MPI | P34949 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.65 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11007437 | 0.86 | KMT2A (0.71) | KDM4ETDP1KMT2AMEN1MAPT | |
| SCHEMBL9354766 | 0.86 | KDM4E (0.74) | KDM4ETDP1KMT2AMEN1MAPT | |
| SCHEMBL31298181 | 0.86 | KDM4E (0.74) | KDM4ETDP1KMT2AMEN1MAPT | |
| SCHEMBL10654171 | 0.85 | KMT2A (0.62) | KDM4ETDP1KMT2AMEN1MAPT | |
| SCHEMBL2805779 | 0.85 | KDM4E (1.00) | KDM4ETDP1KMT2AMEN1MAPT | |
| SCHEMBL29415434 | 0.85 | KDM4E (1.00) | KDM4ETDP1KMT2AMEN1MAPT | |
| SCHEMBL1228041 | 0.84 | KDM4E (0.62) | KDM4ETDP1KMT2AMEN1MAPT | |
| SCHEMBL2284247 | 0.84 | KDM4E (0.69) | KDM4ETDP1KMT2AMEN1MAPT | |
| SCHEMBL2069110 | 0.81 | KMT2A (0.78) | KDM4EKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL476755 | 0.81 | KDM4E (0.72) | KDM4ETDP1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0012925-B1 | QUINOLON-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-11-10 | — | — | EP | claimed |
| CN-104610144-A | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMA | 2015-05-13 | — | — | CN | disclosed |
| US-8962598-B2 | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators | IMMUNAHR AB (SE) | 2015-02-24 | — | — | US | disclosed |
| CN-102015705-B | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2013-11-13 | — | — | CN | disclosed |
| EP-2627638-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. | Immunahr AB (SE) | 2013-08-21 | — | — | EP | disclosed |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | IMMUNAHR AB (SE) | 2013-08-08 | — | — | US | disclosed |
| WO-2012050500-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. | PETTERSSON LARS (SE) | 2012-04-19 | — | — | WO | disclosed |
| CN-102015705-A | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2011-04-13 | — | — | CN | disclosed |
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-12-31 | — | — | US | disclosed |
| CN-101495186-A | Inhibitors of undecaprenyl pyrophosphate synthase | NOVARTIS AG (CH) | 2009-07-29 | — | — | CN | disclosed |
| US-4281131-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-4187309-A | ANTIALLERGENS, ANTIHISTAMINES | SANDOZ, INC. (US) | 1980-02-05 | — | — | US | disclosed |
| US-4187309-A | ANTIALLERGENS, ANTIHISTAMINES | SANDOZ, INC. (US) | 1980-02-05 | — | — | US | disclosed |
| US-4187309-A | ANTIALLERGENS, ANTIHISTAMINES | SANDOZ, INC. (US) | 1980-02-05 | — | — | US | disclosed |
| EP-0000153-A1 | 4-Hydroxy-2-quinolinone-3-carboxylic acids, their preparation and pharmaceutical compositions containing them. | SANDOZ AG (CH) | 1979-01-10 | — | — | EP | disclosed |
| EP-0000153-A1 | 4-Hydroxy-2-quinolinone-3-carboxylic acids, their preparation and pharmaceutical compositions containing them. | SANDOZ AG (CH) | 1979-01-10 | — | — | EP | disclosed |
| EP-0000153-A1 | 4-Hydroxy-2-quinolinone-3-carboxylic acids, their preparation and pharmaceutical compositions containing them. | SANDOZ AG (CH) | 1979-01-10 | — | — | EP | disclosed |
| US-4119720-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1978-10-10 | — | — | US | disclosed |
| US-4119720-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1978-10-10 | — | — | US | disclosed |
| US-4119720-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1978-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | KDM4E 3718/4885TDP1 1147/4885KMT2A 4780/4885 |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | AHR, HRH4, ARNT | KDM4E 1142/4885TDP1 1823/4885KMT2A 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.